Skip to main content

Table 1 Univariate analysis of axillary evaluation and patient characteristics among those who underwent mastectomy

From: DCIS and axillary nodal evaluation: compliance with national guidelines

  

Mastectomy Cohort (n = 31,912)

Breast Conservation Cohort (n = 55,349)

Variable

 

Yes

No

p-Value

Yes

No

p-Value

Year of Diagnosis

1998

828(74.4%)

285(25.6%)

<0.01

265(20.1%)

1051(79.9%)

<0.01

1999

821(72.8%)

306(27.2%)

 

303(18.8%)

1311(81.2%)

 

2000

838(70.1%)

358(29.9%)

 

369(21.1%)

1378(78.9%)

 

2001

896(73.7%)

319(26.3%)

 

437(23.6%)

1412(76.4%)

 

2002

895(72.4%)

342(27.6%)

 

503(24.1%)

1582(75.9%)

 

2003

1146(74.9%)

385(25.1%)

 

819(26.5%)

2272(73.5%)

 

2004

1203(82.1%)

262(17.9%)

 

895(28.5%)

2250(71.5%)

 

2005

1345(82.5%)

286(17.5%)

 

1008(29.9%)

2365(70.1%)

 

2006

1544(85.1%)

270(14.9%)

 

1216(32.3%)

2553(67.7%)

 

2007

1939(87.5%)

278(12.5%)

 

1539(34.1%)

2979(65.9%)

 

2008

3471(91.3%)

329(8.7%)

 

2611(36.9%)

4457(63.1%)

 

2009

4142(91.3%)

397(8.7%)

 

3041(37.9%)

4981(62.1%)

 

2010

4151(93.5%)

287(6.5%)

 

2904(43%)

3851(57%)

 

2011

4286(93.4%)

303(6.6%)

 

3069(43.9%)

3928(56.1%)

 

Race

Black

3144(86.5%)

491(13.5%)

0.52

2087(34.1%)

4039(65.9%)

0.02

White

22682(86.2%)

3638(13.8%)

 

15954(34.5%)

30246(65.5%)

 

Other

1335(85.3%)

230(14.7%)

 

761(31.9%)

1628(68.1%)

 

Age

18–46

7089(88.5%)

918(11.5%)

<0.01

5023(34.8%)

9392(65.2%)

<0.01

47–55

7440(87.2%)

1096(12.8%)

 

5137(34.9%)

9584(65.1%)

 

56–65

6549(86.8%)

992(13.2%)

 

4743(35.6%)

8594(64.4%)

 

>65

6427(82.1%)

1401(17.9%)

 

4076(31.7%)

8800(68.3%)

 

Facility Type

Community Cancer Program

2175(81%)

511(19%)

<0.01

2133(36.4%)

3731(63.6%)

<0.01

Comprehensive Community Cancer Program

16873(86%)

2757(14%)

 

12474(36.6%)

21632(63.4%)

 

Academic/Research Program

8457(88.1%)

1139(11.9%)

 

4372(28.4%)

11007(71.6%)

 

Facility Location

Midwest

6742(86.2%)

1079(13.8%)

<0.01

4169(31.4%)

9128(68.6%)

<0.01

Northeast

5267(86.7%)

810(13.3%)

 

3612(27.9%)

9319(72.1%)

 

South

10642(86.8%)

1623(13.2%)

 

7738(41.2%)

11023(58.8%)

 

West

4854(84.4%)

895(15.6%)

 

3460(33.4%)

6900(66.6%)

 

Primary Site

Nipple areolar

223(79.1%)

59(20.9%)

<0.01

94(26.7%)

258(73.3%)

<0.01

Central

1766(85.1%)

310(14.9%)

 

1047(30.7%)

2368(69.3%)

 

Upper inner

1883(86.5%)

294(13.5%)

 

1629(34.1%)

3153(65.9%)

 

Lower inner

1672(87.3%)

244(12.7%)

 

1123(32.9%)

2288(67.1%)

 

Upper outer

7503(86.4%)

1185(13.6%)

 

7413(36.7%)

12801(63.3%)

 

Lower outer

1861(86.8%)

284(13.2%)

 

1240(33.9%)

2418(66.1%)

 

Axillary tail

31(86.1%)

5(13.9%)

 

51(48.1%)

55(51.9%)

 

Overlapping lesion

6113(88%)

835(12%)

 

3723(34.2%)

7175(65.8%)

 

NOS

6453(84.4%)

1191(15.6%)

 

2659(31.2%)

5854(68.8%)

 

Tumor Size

≤1 cm

4921(83.5%)

970(16.5%)

<0.01

5605(30.3%)

12878(69.7%)

<0.01

>1 cm, ≤2 cm

5846(88.7%)

745(11.3%)

 

4903(40.7%)

7139(59.3%)

 

>2 cm, ≤3 cm

1762(90%)

195(10%)

 

940(43.9%)

1199(56.1%)

 

>3 cm, ≤4 cm

1376(89.6%)

159(10.4%)

 

647(45.3%)

781(54.7%)

 

>4 cm, ≤5 cm

1178(91.7%)

106(8.3%)

 

363(45.1%)

441(54.9%)

 

>5 cm

2526(92.8%)

196(7.2%)

 

535(45.2%)

648(54.8%)